Table 3. Survival HRs according to EGFR mutation status in phase III clinical trials with EGFR tyrosine kinase inhibitors.

Trial	N	HR	95% CI	P-value	Biomarker by treatment interaction P-value
BR.21 (Shepherd et al, 2005; Tsao et al, 2005; Zhu et al, 2008)
EGFR mutated	30	0.55	0.25–1.19	0.1217	0.47
EGFR wild-type	176	0.74	0.52–1.05	0.0924
ISEL (Thatcher et al, 2005; Hirsch et al, 2006)
EGFR mutated	26	NR	NR	NR	NR
EGFR wild-type	189
SATURN (Brugger et al, 2009; Cappuzzo et al, 2010b)a
EGFR mutated	22	0.10	0.04–0.25	<0.0001
EGFR wild-type	199	0.78	0.63–0.96	0.0195
ATLAS (Johnson et al, 2009)a
EGFR mutated	52	0.44	0.22–0.86	NR	NR
EGFR wild-type	295	0.85	0.64–1.13	NR
INTEREST (Kim et al, 2008; Douillard et al, 2010)
EGFR mutated		0.83	0.41–1.67	0.60	0.59
EGFR wild-type	NR	1.02	0.78–1.33	0.91
IPASS (Fukuoka et al, 2009; Mok et al, 2009)a
EGFR mutated	261	0.48	0.36–0.64	<0.001	<0.0001
EGFR wild-type	176	2.85	2.05–3.98	<0.001
WJTOG3405 (Mitsudomi et al, 2010)a,b	177	0.489	0.336–0.710	<0.0001	NA
NEJ002 (Maemondo et al, 2010)a,c	230	0.36	0.25–0.51	<0.001	NA
CTONG 0802 (Zhou et al, 2010)	154	0.16	0.10–0.26	<0.0001	NA

Abbreviations: ATLAS=Avastin and Tarceva or Avastin and pLAcebo in patients with NSCLC; CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio; ISEL=Iressa Survival Evaluation in Lung Cancer; INTEREST=Iressa NSCLC Trial Evaluating Response and Survival versus Taxotere; IPASS=Iressa Pan-Asian Study; NR=not reported; NA=not applicable; SATURN=Sequential Tarceva in Unresectable NSCLC; TKI=tyrosine kinase inhibitor.

^aHR for progression-free survival.

^bGefitinib vs cisplatin/docetaxel.

^cGefitinib vs paclitaxel/carboplatin.